Latuda (lurasidone) is not a mood stabilizer. It is classified as an atypical antipsychotic. The FDA has never labeled it as a mood stabilizer, and it works through an entirely different mechanism than traditional mood stabilizers like lithium or valproate. That said, Latuda is FDA-approved for treating bipolar depression, which is why the two categories get confused so often.
How the FDA Classifies Latuda
The FDA approves Latuda for three specific uses: schizophrenia in adults and adolescents (ages 13 to 17), bipolar I depression as a standalone treatment in adults, and bipolar I depression alongside lithium or valproate in adults. The bipolar depression approval is what leads many people to think of it as a mood stabilizer, but treating one phase of bipolar disorder doesn’t make a drug a mood stabilizer any more than treating a fever makes ibuprofen an antibiotic.
Traditional mood stabilizers, like lithium, are defined partly by their ability to treat and prevent both poles of bipolar disorder: mania and depression. Latuda has no FDA approval for treating or preventing mania. Its role is narrower, focused specifically on the depressive episodes that occur in bipolar I disorder.
Why the Distinction Matters
Mood stabilizers and atypical antipsychotics work on the brain in fundamentally different ways. Latuda primarily blocks dopamine and serotonin receptors. It has strong binding at dopamine D2 receptors and two serotonin receptor types (5-HT2A and 5-HT7), and it partially activates another serotonin receptor (5-HT1A). This receptor profile is what gives it antidepressant effects in bipolar disorder without the risk of triggering a manic switch that traditional antidepressants carry.
Lithium, by contrast, works through broader cellular signaling pathways that affect how neurons communicate across the board. This is part of why lithium can address both mania and depression, while Latuda targets the depressive side more precisely. Atypical antipsychotics as a class tend to act faster against acute mania than lithium does (lithium can take six to seven weeks in younger patients), but Latuda specifically isn’t used for that purpose.
How Well Latuda Works for Bipolar Depression
In clinical trials, Latuda produced meaningful improvement in depressive symptoms over six weeks. In a study of adolescents aged 10 to 17, those taking Latuda saw their depression scores drop by 21 points on a standard rating scale, compared to 15.3 points for placebo. That translates to a moderate effect size of 0.45, meaning it outperformed placebo by a clinically noticeable margin. Results were statistically significant.
The effective dose range for bipolar depression is 20 to 120 mg per day when used with lithium or valproate, and 20 to 80 mg per day when used alone. No gradual dose increase is required at the start, which simplifies the process compared to many psychiatric medications.
Latuda Combined With Actual Mood Stabilizers
One of Latuda’s approved uses is as an add-on to lithium or valproate, both of which are true mood stabilizers. This combination approach makes sense precisely because Latuda and mood stabilizers do different things. A longer-term study looked at whether adding Latuda to lithium or valproate could prevent future mood episodes over 28 weeks. The combination reduced the probability of any mood episode recurrence by 29%, though this result didn’t reach statistical significance for the full group.
Where the results were more compelling: patients whose most recent episode was depressive saw a 43% reduction in recurrence risk with Latuda added. Patients who weren’t rapid-cycling (meaning they don’t cycle through mood episodes frequently) also saw significant benefit. The combination was well tolerated over the long term, with minimal effects on weight or metabolic health.
Side Effects Compared to Other Options
Latuda’s side effect profile is one reason prescribers choose it over other atypical antipsychotics for bipolar depression. It has very low affinity for histamine and muscarinic receptors, which are the receptors responsible for the weight gain and sedation that make drugs like quetiapine and olanzapine harder to tolerate long-term.
The most notable side effect is akathisia, a feeling of inner restlessness or an inability to sit still. In schizophrenia trials, about 13% of people on Latuda experienced this compared to 3% on placebo. In bipolar depression studies with adjunctive therapy, the rate was around 11% versus 5% on placebo. Akathisia tends to be dose-related: at 20 mg, roughly 6% of patients experienced it, while at 120 mg, the rate rose to 22%.
Where Latuda Fits in Bipolar Treatment
Think of bipolar disorder treatment as having different tools for different phases. Mood stabilizers like lithium serve as the foundation, preventing swings in both directions and keeping things level over time. Latuda fills a more specific role: pulling someone out of a bipolar depressive episode, either on its own or layered on top of a mood stabilizer that’s already in place. It is not designed to prevent mania, and it is not a long-term mood-leveling agent in the way lithium is.
The informal use of “mood stabilizer” in everyday conversation has blurred over the years to include any medication prescribed for bipolar disorder. But pharmacologically, Latuda belongs firmly in the atypical antipsychotic category. If your prescriber has recommended it for bipolar depression, it’s being used for one of its approved purposes, just not as a mood stabilizer in the traditional sense.